Alicia Gilsenan

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter by Year

Filter by Publication Type

Filter by Publication Topic

Search Results

Physician awareness of the safe use of cyproterone acetate in Europe: A survey on the effectiveness of additional risk minimization measures

Post-authorization safety studies of acute liver injury and severe complications of urinary tract infections in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting

Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting

Risk of major cardiovascular and cerebrovascular events in users of Lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: A population-based cohort study

Teriparatide and osteosarcoma risk: History, science, elimination of boxed warning, and other label updates

Adapting to the dynamic landscape of the COVID-19 pandemic: Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community, August 26-28, 2022, Copenhagen, Denmark

Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study

Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: A literature review

Identification and validation of major cardiovascular events in the United Kingdom data sources Included in a multi-database post-authorization safety study of prucalopride

Long-term cancer surveillance: Results from the Forteo Patient Registry Surveillance Study

Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom

Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data

No evidence of off-label use of olodaterol and indacaterol in Denmark, France, and the Netherlands: A drug utilization study

Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24-28, 2019: A multinational population-based cohort study

Assessing the incidence of osteosarcoma among teriparatide users via linkage of data from Medicare Part D and multiple state cancer registries in the United States

Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: A pilot study

Predictors of response outcomes for research recruitment through a central cancer registry: Evidence from 17 recruitment efforts for population-based studies

The Forteo Patient Registry linkage to multiple state cancer registries: Study design and results from the first 8 years

Limitations in reporting “benefit‐risk” across therapeutic areas in medical device literature